The 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as they discussed the latest clinical updates in the field. In this podcast series, you will hear the latest advances in the treatment and management of lymphoma and gain an insight into the sessions that took place at this year’s meeting.
In this podcast, Tanya Siddiqi, MD, City of Hope, Duarte, CA, and Nirav Shah, MD, Medical College of Wisconsin, Milwaukee, WI, discuss the role of BTK inhibitors and degraders in NHL. Following this, you will hear from Martin Hutchings, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, Marion Subklewe, MD, Ludwig-Maximilians University, Munich, Germany, Mazyar Shadman, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, and Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, who discuss the growing role of bispecific antibodies, including glofitamab, epcoritamab and odronextamab, in this disease setting.
MPN highlights at ASH 2023: novel agents & ongoing clinical trials in ET, PV and MF
iwNHL 2023 Session V: Expanding the CAR platform in NHL
iwCLL 2023: The role of continuous BTKis, approaching Richter’s transformation & addressing the underrepresentation of elderly patients in trials
Unmet needs in AL amyloidosis, novel treatment strategies being explored, and the role of CHIP
iwNHL 2023 Session III: Recent updates with the use of antibody-drug conjugates in NHL
MPN diagnosis & treatment: novel agents in PV, clinical guidance for the use of JAK inhibitors & the growing role of combination approaches
iwNHL 2023 Session II: The evolving treatment landscape in mantle cell lymphoma
iwNHL 2023 Session I: Updates on the biology and treatment of T-cell lymphoma
iwAL 2023 Session IV: transplantation and immunotherapies in AML: improving patient outcomes
Classifying frailty and approaching elderly patients with lymphoma
Updates on the diagnosis, risk stratification and treatment of lower-risk MDS
iwAL 2023 Session III: The relevance of TP53 mutation in AML
iwAL 2023 Session II: Novel treatments in AML: FLT3 inhibitors, combinations, and more
iwAL 2023 Session I: Clonal hematopoiesis in AML, early detection and potential therapeutics
Applications of MRD in multiple myeloma: using MRD to guide treatment decisions
Exploring and comparing the curative potential of CAR-T therapy & bispecific antibodies in R/R DLBCL
Pre-MDS states: improving prognosis, novel therapeutic approaches, and challenges with distinguishing these conditions
Accelerated-phase MPNs: mutational landscape, challenges, and novel treatment strategies being explored
Determining the optimal sequencing of bispecifics and CAR-T cells in multiple myeloma
Create your
podcast in
minutes
It is Free
Good Mood Revolution
Good Nurse Bad Nurse
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
The Peter Attia Drive
The Doctor’s Farmacy with Mark Hyman, M.D.